Drug major Lupin on Tuesday said it has received approval from the US health regulator to market Budesonide Inhalation Suspension single-dose ampoules, used for treating Asthma.
The product approved by the United States Food and Drug Administration (USFDA) is a generic version of AstraZeneca Pharmaceuticals LP’s Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL, Lupin said in a regulatory filing.
Quoting IQVIA MAT September data, Lupin said, the said Asthma drug had annual sales of around $ 474.5 million in the US.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.